definiens: shall mean the manufacturing plans reviewed by the STEERING COMMITTEE pursuant to section 3.2.2 of this AGREEMENT ; 1.1.12 means, with respect to PRODUCT in a particular country in the ROW TERRITORY, a cancer vaccine developed, marketed and SOLD by a third party ( which, for greater certainty, shall exclude an AFFILIATE of a party to this AGREEMENT ) for the treatment and/or prevention of cancer that elicits a MUC1 specific immune response ( but excluding for greater certainty gene therapy products ) and which has an adverse impact on SALES of PRODUCT in such country ; 1.1.13 has the meaning attributed to that term in section 8.1 of this AGREEMENT ; 1.1.14 means that certain adjuvant license agreement dated as of October 20, 2004 with Corixa Corporation, together with all schedules thereto and any amendments to or restatements of such adjuvant license agreement ; 1117215.12 Execution Copy Confidential Treatment Requested by [COMPANY] Corporation, File No . 333 - 145995, Exhibit 10.23 4 1.1.15 means that certain license agreement dated November 22, 1996 with the Dana - Farber Cancer Institute, Inc., together with all schedules thereto and any amendments to or restatements of such license agreement ; 1.1.16 shall mean the development plans reviewed by the STEERING COMMITTEE pursuant to section 3.2.1 of this AGREEMENT ; 1.1.17 means, with respect to PRODUCT in a particular country in the TERRITORY, a third party retained to market, promote and/or sell PRODUCT in such country, but excluding for greater certainty wholesalers and any such third party in circumstances where the laws of such country require the use of such third party to market, promote and/or sell PRODUCT in such country ; 1.1.18 has the meaning attributed to that tenn in section 5.12.6 of this AGREEMENT